Regence · Weight Loss

Regence coverage for Zepbound (Weight Loss)

Employer / Commercial Insurance

Depends on your plan's benefit

Coverage requires that the member benefit contract allows for coverage of medications for weight loss in obesity/overweight; weight loss must NOT be excluded from the pharmacy benefit

What you need to qualify

Age 18 and older
BMI of 30 or higher
BMI of 27 or higher with a weight-related condition (HTN, dyslipidemia, T2DM, pre-diabetes, insulin_resistance, OSA, CVD, and symptomatic_arthritis_lower_extremities)
6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adults with obesity

All of:

Member benefit contract allows coverage of medications for weight loss in obesity/overweight
Age >= 18 years
BMI >= 30 kg/m2
Attestation medication will be used with lifestyle modification

Adults with overweight and comorbidity

All of:

Member benefit contract allows coverage of medications for weight loss in obesity/overweight
Age >= 18 years
BMI >= 27 kg/m2
Attestation medication will be used with lifestyle modification

Plus any one of:

Hypertension
Dyslipidemia
Type 2 diabetes mellitus
Pre-diabetes
Insulin resistance
Obstructive sleep apnea
Cardiovascular disease
Symptomatic arthritis of lower extremities

Continuation of therapy - established on therapy prior to current health plan membership

All of:

Patient was established on therapy prior to current health plan membership
Documentation that medication was covered by another health plan
Clinical benefit such as disease stability
Member benefit contract allows coverage of medications for weight loss in obesity/overweight

Documentation to bring

Clinical documentation (e.g., chart notes) confirming BMI >= 30 kg/m2 (obesity) OR BMI >= 27 kg/m2 with at least one weight-related comorbid condition (overweight)
Attestation that medication will be used concomitantly with lifestyle modification
For continuation: attestation of >= 5% body weight reduction from pretreatment baseline OR documentation that dose is currently being titrated upwards

Quantity limits

all strengths — 4 pens per 28 days

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight and Adults (>=18 years): >= 5% body weight reduction from pretreatment baseline OR dose currently being titrated upwards. Attestation required that medication continues to be used with lifestyle modification. Benefit contract coverage eligibility re-verified at each renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Co-administration with other weight loss medications (Contrave, Qsymia, or other GLP-1 agents in this policy) considered investigational
Used for type 2 diabetes without obesity or overweight — considered not medically necessary
Diabetic ketoacidosis (DKA)
Type 1 diabetes

Policy note: Policy covers Zepbound for weight loss in adults only (age >= 18); pediatric use of Zepbound is not included (only liraglutide/Saxenda and Wegovy are coverable for obesity in pediatrics per policy note). Coverage is gated on member benefit contract allowing weight loss medication coverage. Zepbound is NOT listed as a covered option for pediatric obesity in this policy.

Policy effective July 15, 2026 · verified July 16, 2026 · source: dru787reg.pdf

ACA Marketplace

Depends on your plan's benefit

Coverage requires that the member benefit contract allows for coverage of medications for weight loss in obesity/overweight. Not coverable when the member benefit contract excludes obesity/overweight treatments.

What you need to qualify

Age 18 and older
BMI of 30 or higher
BMI of 27 or higher with a weight-related condition (HTN, dyslipidemia, T2DM, pre-diabetes, insulin_resistance, OSA, CVD, and symptomatic_arthritis_lower_extremities)
6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult obesity (>=18 years)

All of:

Member benefit contract allows coverage of medications for weight loss in obesity/overweight
Age >= 18 years
BMI >= 30 kg/m2
Attestation that medication will be used with lifestyle modification

Adult overweight with comorbidity (>=18 years)

All of:

Member benefit contract allows coverage of medications for weight loss in obesity/overweight
Age >= 18 years
BMI >= 27 kg/m2
Attestation that medication will be used with lifestyle modification

Plus any one of:

Hypertension
Dyslipidemia
Type 2 diabetes mellitus (T2DM)
Pre-diabetes
Insulin resistance
Obstructive sleep apnea (OSA)
Cardiovascular disease (CVD)
Symptomatic arthritis of lower extremities

Documentation to bring

Clinical documentation confirming BMI >= 30 kg/m2 (obesity) OR BMI >= 27 kg/m2 with at least one weight-related comorbid condition
Attestation that medication will be used with lifestyle modification (dietary/caloric restriction, exercise, weight management program, nutritional counseling, behavioral therapy)
Verification that member benefit contract allows coverage of medications for weight loss in obesity/overweight

Quantity limits

all strengths — 4 pens/28 days

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight and Adults (>=18 years): >= 5% body weight reduction from pretreatment baseline OR dose currently being titrated upwards. Member benefit contract must continue to allow coverage. Attestation required that medication will continue to be used with lifestyle modification. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Co-administration with other medications for obesity or overweight (including Contrave, Qsymia) is considered investigational and not covered
Use for type 2 diabetes without obesity or overweight is considered not medically necessary
Zepbound is NOT coverable for obesity in pediatric patients (ages 12-17); only liraglutide generic/Saxenda and Wegovy are coverable in pediatrics
Type 1 diabetes

Policy note: Policy dru787 covers non-diabetic indications only. Mounjaro (tirzepatide for diabetes) is addressed in a separate policy (dru750). Zepbound is NOT listed as coverable for pediatric obesity (12-17 years) — only liraglutide and Wegovy are covered in that age group. The weight loss coverage for Zepbound requires the member benefit contract to allow weight loss medication coverage.

Policy effective March 15, 2026 · verified June 3, 2026 · source: dru787reg.pdf

All Zepbound policies under Regence · Check your card